B+
Bull case
25%
Probability
Target price
$45.66
+35.4% vs current
INDV
IndiviorANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$33.36
-1.0% vs current
B-
Bear case
25%
Probability
Target price
$26.34
-21.9% vs current
AI sentiment snapshot
Latest data as of 2025-12-07
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.7
Score
AI commentary
Market tone is cautious-to-neutral: official close data show a mid-$30s anchor and investors are monitoring earnings and commercial cadence for direction [#RA-2025-12-05]. Short-term chatter focuses on reimbursement and litigation risk, while longer-term sentiment hinges on sustained U.S. uptake [#RA-2025-12-05]. Overall, headlines currently favor a watchful stance rather than outright conviction.
RankAlpha Sentiment AI - 2025-12-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly earnings / updated guidanceHigh impact
Quarterly results and management commentary can reprice expectations for margins and US commercial momentum; typical headline mover for INDV [#RA-2025-12-05].
-catalystRegulatory, litigation, or generic-entry shockHigh impact
Adverse regulatory decisions or faster-than-expected generic competition could cause sharp downside; historically a material risk for specialty pharma names [#RA-2025-12-05].
-catalystCommercial uptake / market-share gains for core OUD productsHigh impact
Sustained volume growth or better payer coverage for Indivior's opioid-use-disorder (OUD) franchise would support upside vs. peers; impact depends on US formulary trends [#RA-2025-12-05].
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-07 • Updated nightlySource: Internal modelMethodology